Alexion Pharmaceuticals, until recently seen as one of biotech’s biggest success stories, is eliminating roughly 600 jobs and moving its headquarters to Boston amid federal investigations and pressure to cut costs.

The company made its name on Soliris, a treatment for rare diseases that — at a cost of about $700,000 a year — is also the world’s most expensive drug. But after a series of pipeline disappointments and an ill-advised $8.4 billion acquisition, Alexion is facing an uncertain future.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy